Trial Profile

A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Eylea Compared to Prn Eylea Monotherapy in Neovascular AMD

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorolanib (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms APEX
Sponsors Tyrogenex; Xcovery Vision

Most Recent Events

25 Jun 2020 Primary endpoint has been met. (Mean Change in Visual Acuity Score From Day -1 to Week52), as per results published in the British journal of ophthalmology.
25 Jun 2020 Results published in the British journal of ophthalmology
30 May 2018 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com